The Study of Omega-3 supplementation Effect on Lipid Profiles in Hemodialysis Patients
Not Applicable
- Conditions
- hemodialysis patients.End-stage renal disease
- Registration Number
- IRCT2013081214333N1
- Lead Sponsor
- Vice Chancellor for Research Affairs, Kermanshah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Inclusion criterias: patient's willingness to cooperate, and at least 6 months of dialysis starting time. Exclusion criterias: presence of bleeding and warfarin anticoagulation drugs usage or anti-thrombotic (aspirin, ticlopidine, dipyridamole and clopidogrel); diabetes; hepatitis, and other infectious diseases; body mass index less than 18.5 or more than 30 kg/ m2; steroidal and non-steroidal anti-inflammatory drugs; omega-3 fatty acids supplements and vitamins E or C within two months before the study .
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cholestrol. Timepoint: week,0,10. Method of measurement: by cell counter.;Triglycerid. Timepoint: week,0,10. Method of measurement: by sell counter.;H.d.L. Timepoint: week,0,10. Method of measurement: by cell counter.;L.D.L. Timepoint: week,0,10. Method of measurement: by cell counter.;Serum alboumin. Timepoint: weak ,0,10. Method of measurement: by sell counter.
- Secondary Outcome Measures
Name Time Method